Efficacy and safety of anakinra in non-COVID-19 related ARDS. ESKA study.

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-518125-15-00

Acronym

CARR-ARDS-2021

Enrollment

Registered

2024-11-18

Start date

Unknown

Completion date

Unknown

Last updated

2024-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute respiratory distress syndrome (ARDS)

Brief summary

The main aim of this study is to evaluate ventilation-free days.

Detailed description

- 28-day mortality; - ICU mortality; - In-hospital mortality; - Improved PaO2/FiO2 ratio (measurement at day 0 and day 28); - Driving pressure reduction (measurement at day 0 and day 28); - Reduction peak pressure (measurement at day 0 and day 28); - Reduction plateau pressure (measurement at day 0 and day 28); - Days free from multi-organ damage calculated by Sequential Organ Failure Assessment methodology (SOFA) score (SOFA score <2) at day 28

Interventions

DRUGKineret 100 mg/0.67 ml solution for injection in pre-filled syringe.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
The main aim of this study is to evaluate ventilation-free days.	—

Secondary

Measure	Time frame
- 28-day mortality; - ICU mortality; - In-hospital mortality; - Improved PaO2/FiO2 ratio (measurement at day 0 and day 28); - Driving pressure reduction (measurement at day 0 and day 28); - Reduction peak pressure (measurement at day 0 and day 28); - Reduction plateau pressure (measurement at day 0 and day 28); - Days free from multi-organ damage calculated by Sequential Organ Failure Assessment methodology (SOFA) score (SOFA score <2) at day 28	—

Measure

Time frame

—

Countries

Italy

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026